What about canakinumab? Can I buy it in Guangdong?
Long-term use of steroids to treat systemic juvenile idiopathic arthritis (SJIA) can result in slower growth and delayed puberty. A pivotal phase III clinical study showed that 45% of SJIA patients using canakinumab (code: ACZ885), a fully human monoclonal antibody developed by Novartis, can reduce the use of glucocorticoids after 28 weeks (P<0.000 1). It inhibits the occurrence of inflammation by continuously neutralizing the key inflammatory mediator interleukin (IL)-1β. It is currently marketed in more than 50 countries under the trade name Iaris for the treatment of a rare disease - Cryopyrin protein-associated periodic syndrome (CAPS).
Can canakinumab be purchased in Guangdong?
Regarding this issue, the editor can only unfortunately tell you that canakinumab is not yet available in China. In other words, no hospital or pharmacy in Guangdong sells this drug. Many patients have no way to seek medicine and will choose to go overseas. That is the only life-saving way to purchase medicine. But patients who have been there know that this overseas drug purchasing journey is not easy. Language barriers, authenticity of drugs, and round-trip travel expenses are all heavy burdens on patients' shoulders. At this time, patients may wish to let the domestic overseas medical service medical institution Medical Companion Travel help you purchase canakinumab. Medical Companion Travel is a reliable organization that can guarantee the authenticity of the drug. On the other hand, it can save you all the problems of traveling back and forth overseas. It is very convenient and safe. If you have more questions about canakinumab, please contact Medical Companion Travel, and Medical Companion Travel will serve you wholeheartedly.
Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.
Recommended related hot articles:
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)